Metal-based antitumor compounds: beyond cisplatin.
Peter V Simpson
1
,
Nima Maheshkumar Desai
2
,
Ilaria Casari
2
,
Massimiliano Massi
1
,
Marco Falasca
2
Publication type: Journal Article
Publication date: 2019-01-15
scimago Q3
wos Q2
SJR: 0.501
CiteScore: 4.8
Impact factor: 3.4
ISSN: 17568919, 17568927
PubMed ID:
30644327
Drug Discovery
Pharmacology
Molecular Medicine
Abstract
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
|
|
|
Applied Organometallic Chemistry
6 publications, 5.61%
|
|
|
Dalton Transactions
6 publications, 5.61%
|
|
|
Journal of Inorganic Biochemistry
5 publications, 4.67%
|
|
|
International Journal of Molecular Sciences
4 publications, 3.74%
|
|
|
Molecules
4 publications, 3.74%
|
|
|
Pharmaceutics
3 publications, 2.8%
|
|
|
Journal of Biological Inorganic Chemistry
3 publications, 2.8%
|
|
|
European Journal of Medicinal Chemistry
3 publications, 2.8%
|
|
|
Journal of Molecular Structure
3 publications, 2.8%
|
|
|
Chemistry - A European Journal
3 publications, 2.8%
|
|
|
European Journal of Inorganic Chemistry
3 publications, 2.8%
|
|
|
ChemMedChem
3 publications, 2.8%
|
|
|
Journal of Medicinal Chemistry
3 publications, 2.8%
|
|
|
Inorganica Chimica Acta
2 publications, 1.87%
|
|
|
Chemistry and Biodiversity
2 publications, 1.87%
|
|
|
Inorganics
2 publications, 1.87%
|
|
|
RSC Advances
2 publications, 1.87%
|
|
|
MolBank
1 publication, 0.93%
|
|
|
Anti-Cancer Agents in Medicinal Chemistry
1 publication, 0.93%
|
|
|
Journal of Medical Microbiology
1 publication, 0.93%
|
|
|
Future Medicinal Chemistry
1 publication, 0.93%
|
|
|
Cells
1 publication, 0.93%
|
|
|
Metabolites
1 publication, 0.93%
|
|
|
Antibiotics
1 publication, 0.93%
|
|
|
Frontiers in Chemistry
1 publication, 0.93%
|
|
|
Russian Chemical Bulletin
1 publication, 0.93%
|
|
|
Journal of Cluster Science
1 publication, 0.93%
|
|
|
Bioorganic Chemistry
1 publication, 0.93%
|
|
|
Journal of Experimental and Clinical Cancer Research
1 publication, 0.93%
|
|
|
Biomolecules
1 publication, 0.93%
|
|
|
1
2
3
4
5
6
|
Publishers
|
5
10
15
20
25
30
|
|
|
Elsevier
28 publications, 26.17%
|
|
|
Wiley
19 publications, 17.76%
|
|
|
MDPI
18 publications, 16.82%
|
|
|
Royal Society of Chemistry (RSC)
11 publications, 10.28%
|
|
|
Springer Nature
8 publications, 7.48%
|
|
|
American Chemical Society (ACS)
7 publications, 6.54%
|
|
|
Bentham Science Publishers Ltd.
3 publications, 2.8%
|
|
|
Taylor & Francis
2 publications, 1.87%
|
|
|
Frontiers Media S.A.
2 publications, 1.87%
|
|
|
Pleiades Publishing
2 publications, 1.87%
|
|
|
Microbiology Society
1 publication, 0.93%
|
|
|
IOP Publishing
1 publication, 0.93%
|
|
|
Hindawi Limited
1 publication, 0.93%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 0.93%
|
|
|
American Society for Microbiology
1 publication, 0.93%
|
|
|
Walter de Gruyter
1 publication, 0.93%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.93%
|
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
107
Total citations:
107
Citations from 2025:
8
(7.47%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Simpson P. V. et al. Metal-based antitumor compounds: beyond cisplatin. // Future Medicinal Chemistry. 2019. Vol. 11. No. 2. pp. 119-135.
GOST all authors (up to 50)
Copy
Simpson P. V., Desai N. M., Casari I., Massi M., Falasca M. Metal-based antitumor compounds: beyond cisplatin. // Future Medicinal Chemistry. 2019. Vol. 11. No. 2. pp. 119-135.
Cite this
RIS
Copy
TY - JOUR
DO - 10.4155/fmc-2018-0248
UR - https://doi.org/10.4155/fmc-2018-0248
TI - Metal-based antitumor compounds: beyond cisplatin.
T2 - Future Medicinal Chemistry
AU - Simpson, Peter V
AU - Desai, Nima Maheshkumar
AU - Casari, Ilaria
AU - Massi, Massimiliano
AU - Falasca, Marco
PY - 2019
DA - 2019/01/15
PB - Taylor & Francis
SP - 119-135
IS - 2
VL - 11
PMID - 30644327
SN - 1756-8919
SN - 1756-8927
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Simpson,
author = {Peter V Simpson and Nima Maheshkumar Desai and Ilaria Casari and Massimiliano Massi and Marco Falasca},
title = {Metal-based antitumor compounds: beyond cisplatin.},
journal = {Future Medicinal Chemistry},
year = {2019},
volume = {11},
publisher = {Taylor & Francis},
month = {jan},
url = {https://doi.org/10.4155/fmc-2018-0248},
number = {2},
pages = {119--135},
doi = {10.4155/fmc-2018-0248}
}
Cite this
MLA
Copy
Simpson, Peter V., et al. “Metal-based antitumor compounds: beyond cisplatin..” Future Medicinal Chemistry, vol. 11, no. 2, Jan. 2019, pp. 119-135. https://doi.org/10.4155/fmc-2018-0248.